
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Helix BioMedix completed a preliminary study designed to evaluate the efficacy of one the company's proprietary peptides, HB64, in reducing severity of mild to moderate acne symptoms.